Edition:
India

Trillium Therapeutics Inc (TRIL.OQ)

TRIL.OQ on NASDAQ Stock Exchange Capital Market

6.75USD
2:29am IST
Change (% chg)

$-0.10 (-1.46%)
Prev Close
$6.85
Open
$6.90
Day's High
$7.00
Day's Low
$6.70
Volume
10,845
Avg. Vol
27,606
52-wk High
$13.30
52-wk Low
$4.10

Latest Key Developments (Source: Significant Developments)

Trillium Therapeutics Inc Files For Mixed Shelf Of Upto $150 Mln
Saturday, 16 Dec 2017 

Dec 15 (Reuters) - Trillium Therapeutics Inc ::TRILLIUM THERAPEUTICS INC FILES FOR MIXED SHELF OF UPTO $150 MILLION - SEC FILING.  Full Article

Matrix Capital Management Co Reports A 16.5 Pct Passive Stake In Trillium Therapeutics
Saturday, 9 Dec 2017 

Dec 8 (Reuters) - Trillium Therapeutics Inc ::MATRIX CAPITAL MANAGEMENT COMPANY LP REPORTS A 16.5 PCT PASSIVE STAKE IN TRILLIUM THERAPEUTICS INC <<>> AS OF NOV 30 - SEC FILING.  Full Article

Trillium announces private placement to fund development of cancer drugs
Wednesday, 15 Nov 2017 

Nov 15 (Reuters) - Trillium Therapeutics Inc -:Trillium announces private placement.Trillium Therapeutics - ‍entered into subscription agreements for sale of 1.95 million shares & 400,000 Series II non-voting convertible first preferred shares​.Trillium Therapeutics - ‍net proceeds from private placement will be used to continue development of TTI-621 in hematologic cancers and solid tumors​.Trillium Therapeutics Inc - ‍subscription agreements for offering at a price of U.S.$8.50 per share.  Full Article

Trillium Therapeutics reports Q3 results
Friday, 10 Nov 2017 

Nov 10 (Reuters) - Trillium Therapeutics Inc :Trillium Therapeutics reports third quarter 2017 financial and operating results.Trillium Therapeutics Inc - ‍Cash and marketable securities of $64.3 million at September 30, 2017​.  Full Article

Trillium Therapeutics doses first patient with TTI-621 in phase 1 solid tumor trial
Tuesday, 31 Jan 2017 

Trillium Therapeutics Inc :Trillium Therapeutics doses first patient with TTI-621 in phase 1 solid tumor trial.  Full Article

Trillium Therapeutics doses first patient with TTI-621 in phase 1 solid tumor trial
Tuesday, 31 Jan 2017 

Trillium Therapeutics Inc :Trillium Therapeutics doses first patient with TTI-621 in phase 1 solid tumor trial.  Full Article

BRIEF-Trillium Therapeutics Inc Files For Mixed Shelf Of Upto $150 Mln

* TRILLIUM THERAPEUTICS INC FILES FOR MIXED SHELF OF UPTO $150 MILLION - SEC FILING Source text : http://bit.ly/2jZxGi0 Further company coverage: